StockData

Ascentage Pharma Group International vs Zai Lab

AAPG and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and ZLAB compare

Zai Lab grew revenue faster over the last twelve months (5.1% versus −41.5% for Ascentage Pharma Group International).

Zai Lab keeps more of each dollar of sales as profit, with a net margin of −41.9% compared with −216% at Ascentage Pharma Group International.

Zai Lab scores higher on the StockData Score (7 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGZLAB
Size and price
Market cap–$36.5B
Share price$13.14$23.53
Change, 1 year−61.7%8.2%
Change, 5 years–−69.4%
Beta (5Y)1.431.45
Employees7671,784
StockData Score
Total score37 (better)
Valuation score00
Growth score11
Performance score13 (better)
Health score13 (better)
Dividend score00
Valuation
P/S–81.3×
P/B–60.2×
FCF yield–−0.38%
Fair value–$4.52
Margin of safety–−421%
Growth
Revenue growth (TTM)−41.5%5.1% (better)
Revenue growth, 5Y average–56.5%
Profitability
Gross margin91.5% (better)56.5%
Operating margin–−58.7%
Net margin−216%−41.9% (better)
FCF margin−209%−31.0% (better)
Return on equity−156%−26.9% (better)
Return on invested capital–−90.4%
Financial health
Debt / equity1.500.39 (better)
Interest coverage–−44.1×
Current ratio1.792.13 (better)
Altman Z-score–43.47
Piotroski F-score–4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%2.8%
Held by insiders13.0%0.67%
Insider net buying, 12 months–−$10.7M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.